Breaking News

Tweet TWEET

Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results Conference Call and Webcast

  Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results Conference
  Call and Webcast

Business Wire

RALEIGH, N.C. -- February 13, 2014

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company
will report fourth quarter and full year 2013 financial results following the
close of the U.S. financial markets on Thursday, February 27, 2014.

The Company will host a conference call at 4:30 p.m. ET on Thursday, February
27, 2014. Interested parties can access the conference call by way of web cast
or telephone. The live web cast will be available at www.salix.com. A replay
of the web cast will be available at the same location. The telephone numbers
to access the live conference call are (888) 339-3507 (U.S. and Canada) or
(719) 325-2276 (international.) The access code for the live call is 198635.
The telephone numbers to access the replay of the call are (888) 203-1112
(U.S. and Canada) or (719) 457-0820 (international). The access code for the
replay is 6025289.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina,
develops and markets prescription pharmaceutical products and medical devices
for the prevention and treatment of gastrointestinal diseases. Salix’s
strategy is to in-license late-stage or marketed proprietary therapeutic
products, complete any required development and regulatory submission of these
products, and commercialize them through the Company’s 500-member specialty
sales force.

Salix trades on the NASDAQ Global Select Market under the ticker symbol
“SLXP”.

For more information, please visit our Website at www.salix.com or contact the
Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook
(www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page
and web site is not incorporated in our SEC filings.

Contact:

Salix Pharmaceuticals
Adam C. Derbyshire
Executive Vice President and Chief Financial Officer
919-862-1000
or
G. Michael Freeman
Associate Vice President, Investor Relations and Corporate Communications
919-862-1000
 
Press spacebar to pause and continue. Press esc to stop.